In 2012 the patent “Use of YTX and analogues and derivatives for treating and/or preventing neurodegenerative diseases linked to tau and β-amyloid” was filed by Botana et al. [10], which is very promising in terms of the applicability of YTX in AD pathology. This evidence concerns the gene MAPT and neurodegenerative disease.